



1648
121

PATENT

Attorney Docket No.: 37921-151956

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of :
STEPHEN ALISTER LOCARNINI et al. :
Serial No.: 09/831,686 : Group Art Unit:
1648 :
Filed: July 31, 2001 : Examiner:
Not Yet Assigned :
For: BIOLOGICAL COMPOSITIONS, :
COMPONENTS THEREOF AND USES THEREFOR :
Confirmation No.: 7052 :

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying Form PTO-1449.

The Examiner is respectfully requested to review the items listed on the attached form and make them of record in the instant application as required by M.P.E.P. §609. It is

CERTIFICATE OF MAILING
UNDER 37 C.F.R. 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BY

DATE:

Ms. Dennis M. Collins
August 19, 2005


requested that the Examiner initial the enclosed duplicate Form 1449, and return one copy to the undersigned.

This Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.


This Statement is being submitted before receipt of any office action on the merits. Also, each listed item was first cited in a communication from a foreign patent office in a counterpart foreign application, not more than three months prior to the filing of the herein information disclosure statement. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

STEPHEN ALISTER LOCARNINI et al.

BY 
DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
(215) 988-3312 - Phone
(215) 988-2757 – Fax
Attorney for Applicants

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
37921-151956SERIAL NO.
09/831,686

INFORMATION DISCLOSURE STATEMENT

APPLICANT:
Stephen Alister Locarnini et al.FILING DATE
July 31, 2001GROUP
1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AA	98/21317A	05/22/1998	PCT				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AB	A. Bartholomeusz et al., "Mutations in the Hepatitis B Virus Polymerase Gene that Are Associated With Resistance to Famciclovir And Lamivudine", International Antiviral News, Churchill Livingstone, Edinburgh, GB, vol. 5, no. 8, 1997, pages 123-124.
	AC	Thein Thein Aye et al., "Hepatitis B Virus Polymerase Mutations During Antiviral Therapy in a Patient Following Liver Transplantation", Journal of Hepatology, Munksgaard International Publishers, Copenhagen, DK, vol. 26, no. 5, 1997, pages 1148-1153.
	AD	M. G. Ghany et al., "Hepatitis B Virus S Mutants in Liver Transplant Recipients Who Were Reinfected Despite Hepatitis B Immune Globulin Prophylaxis", Hepatology, Williams and Wilkins, Baltimore, MD, US, vol. 27, no. 1, 1998, pages 213-222.
	AE	A. Bartholomeusz et al., "Significance of Mutations in the Hepatitis B Virus Polymerase Selected by Nucleosides Analogues and Implications for Controlling Chronic Disease", Viral Hepatitis Reviews, Saunders, Philadelphia, PA, US, vol. 4, no. 3, 1998, pages 167-187.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 37921-151956	SERIAL NO. 09/831,686
 INFORMATION DISCLOSURE STATEMENT				APPLICANT: Stephen Alister Locarnini et al.	
				FILING DATE July 31, 2001	GROUP 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AA	98/21317A	05/22/1998	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	A. Bartholomeusz et al., "Mutations in the Hepatitis B Virus Polymerase Gene that Are Associated With Resistance to Famciclovir And Lamivudine", International Antiviral News, Churchill Livingstone, Edinburgh, GB, vol. 5, no. 8, 1997, pages 123-124.
AC	Thein Thein Aye et al., "Hepatitis B Virus Polymerase Mutations During Antiviral Therapy in a Patient Following Liver Transplantation", Journal of Hepatology, Munksgaard International Publishers, Copenhagen, DK, vol. 26, no. 5, 1997, pages 1148-1153.
AD	M. G. Ghany et al., "Hepatitis B Virus S Mutants in Liver Transplant Recipients Who Were Reinfected Despite Hepatitis B Immune Globulin Prophylaxis", Hepatology, Williams and Wilkins, Baltimore, MD, US, vol. 27, no. 1, 1998, pages 213-222.
AE	A. Bartholomeusz et al., "Significance of Mutations in the Hepatitis B Virus Polymerase Selected by Nucleosides Analogues and Implications for Controlling Chronic Disease", Viral Hepatitis Reviews, Saunders, Philadelphia, PA, US, vol. 4, no. 3, 1998, pages 167-187.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.